A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1 by Canal, Frédéric et al.
A kinome siRNA screen identifies HGS as a potential
target for liver cancers with oncogenic mutations in
CTNNB1
Fre´de´ric Canal, Elodie Anthony, Aurianne Lescure, Elaine Del Nery, Jacques
Camonis, Franck Perez, Bruno Ragazzon, Christine Perret
To cite this version:
Fre´de´ric Canal, Elodie Anthony, Aurianne Lescure, Elaine Del Nery, Jacques Camonis, et al.. A
kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mu-
tations in CTNNB1. BMC Cancer, BioMed Central, 2015, 15 (1), pp.1020. <10.1186/s12885-
015-2037-8>. <inserm-01254133>
HAL Id: inserm-01254133
http://www.hal.inserm.fr/inserm-01254133
Submitted on 11 Jan 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH ARTICLE Open Access
A kinome siRNA screen identifies HGS as a
potential target for liver cancers with
oncogenic mutations in CTNNB1
Frédéric Canal1,2,3,4,5*, Elodie Anthony6, Aurianne Lescure6, Elaine Del Nery6, Jacques Camonis6, Franck Perez6,
Bruno Ragazzon1,2,3 and Christine Perret1,2,3,4
Abstract
Background: Aberrant activation of the Wnt/β-catenin pathway is a major and frequent event in liver cancer, but
inhibition of oncogenic β-catenin signaling has proven challenging. The identification of genes that are
synthetically lethal in β-catenin-activated cancer cells would provide new targets for therapeutic drug design.
Methods: We transfected the parental HuH6 hepatoblastoma cell line with a doxycycline-inducible shRNA against
CTNNB1 (gene coding for β-catenin) to obtain an isogenic cell line pair with or without aberrant β-catenin signaling.
Using this hepatoblastoma isogenic cell line pair, we performed a human kinome-wide siRNA screen to identify
synthetic lethal interactions with oncogenic CTNNB1. The phenotypic readouts of the screen were cell proliferation, cell
cycle arrest and apoptosis, which were assessed by image-based analysis. In addition, apoptosis was assessed by flow
cytometric experiments and immunoblotting. The potential synthetic lethal relationship between candidates genes
identified in the screen and oncogenic CTNNB1 was also investigated in a different cellular context, a colorectal HCT116
isogenic cell line pair.
Results: We first determined the experimental conditions that led to the efficient expression of shRNA against
CTNNB1 and maximal reduction of β-catenin signaling activity in response to doxycycline treatment. Following
high throughput screening in which 687 genes coding for kinases and proteins related to kinases (such as
pseudokinases and phosphatases) were targeted, we identified 52 genes required for HuH6 survival. The silencing
of five of these genes selectively impaired the viability of HuH6 cells with high β-catenin signaling: HGS, STRADA,
FES, BRAF and PKMYT1. Among these candidates, HGS depletion had the strongest inhibitory effect on cell growth
and led to apoptosis specifically in HuH6 with high β-catenin activity, while HuH6 with low β-catenin activity
were spared. In addition, HGS was identified as a potential synthetic lethal partner of oncogenic CTNNB1 in the
HCT116 colorectal isogenic cell line pair.
Conclusions: These results demonstrate the existence of crosstalk between β-catenin signaling and HGS.
Importantly, HGS depletion specifically affected cells with uncontrolled β-catenin signaling activity in two
different types of cancer (Hepatoblastoma HuH6 and colorectal HCT116), and thus may represent a new potential
target for novel therapeutic strategies in liver and colorectal cancer.
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Background
Genetic alterations and modifications of the tumor en-
vironment often lead to the apparition of weaknesses
specific to the tumor that could be exploited therapeut-
ically [1]. For instance, the discovery of synthetic lethal
(SL) interactions in cancer cells offers a framework for
the design of highly selective drugs. SL interactions
occur between two genes when mutation of one gene
alone does not alter cellular fitness, but mutation of
both causes cell death [2]. Therefore, the discovery of SL
interactions involving an “undruggable” oncogene may
lead to the identification of new potential therapeutic tar-
gets for cancer treatment. This has been well illustrated by
the LS interaction between BRCA and PARP1. Indeed,
PARP1 inhibitors show promising activity in clinical trials
of breast, ovarian and other cancers associated with BRCA
mutations [3].
Deregulation of the Wnt/β-catenin pathway, which is a
key developmental biology signaling pathway, is a major
event in liver cancer and colorectal tumorigenesis [4, 5],
which were the 2nd and 4th leading causes of death by can-
cer worldwide in 2012, respectively (WHO). Indeed, more
that 50 % of hepatoblastoma (HB) and a third of hepatocel-
lular carcinoma (HCC) display aberrant activation of Wnt/
β-catenin signaling caused by stabilizing mutations of β-
catenin in the CTNNB1 gene [4, 6], while mutations in
APC, which lead to the ectopic activation of Wnt/β-catenin
signaling, are considered the major initiating event in colo-
rectal cancer (CRC) [5, 7]. Thus, the Wnt/β-catenin path-
way has become a prime target for cancer research.
However, despite intensive research during the past decade,
the production of molecules effective against cancers asso-
ciated with uncontrolled Wnt/β-catenin signaling activity
has proven challenging [8]. Hence, the identification of SL
partners of oncogenic β-catenin is a promising strategy for
the discovery of new therapeutic targets for liver cancer.
Here, we used an siRNA kinome library to perform a
high throughput (HT) SL screen of HuH6 isogenic HB
cell lines, and we examined the effect of knockdown on
cell proliferation, the frequency of mitotic events and in-
duction of apoptosis. The depletion of transcripts of five
genes by siRNA led to lethality only in a cellular context
characterized by the aberrant activation of the Wnt/β −
catenin signaling pathway due to a CTNNB1 activating
mutation. One of these genes (HGS) is an SL partner of
oncogenic β-catenin in colorectal HCT116 cancer cells,
suggesting that the LS interaction between HGS and
CTNNB1 is not limited to liver cancer.
Methods
Cell culture, transfection and generation of stable shRNA
clones
Human hepatoblastoma HuH6 cells were grown in
Dulbelcco’s modified Eagle’s medium (DMEM, Gibco,
Life Technologies, Carlsbad, CA) with 10 % fetal bovine
serum and 100 U/ml penicillin/streptomycin. Colorectal
carcinoma HCT116 cells were cultivated in McCoy’s
medium, with 10 % fetal bovine serum, at 37 °C in 5 %
CO2. Parental HuH6 cells were transfected with pTER-β-
catenin plasmid using Lipofectamine 2000 (Life Technolo-
gies) to generate HuH6shCTNNB1 cells [9]. Positive clones
were selected following the culture of cells in 5 μg/ml puro-
mycin for 4 weeks. Isolated colonies were picked using
cloning rings and clones were amplified for 6 weeks and
stored in liquid nitrogen prior to further analysis.
Reporter assay
The TOPflash/FOPflash reporter plasmids (Millipore,
Billerica, MA) were used to determine β-catenin-
induced TCF/LEF transcriptional activity. TOPflash is a
reporter plasmid containing two sets of three copies of
wild-type TCF binding sites driven by the thymidine
kinase minimal promoter located upstream from a
luciferase reporter gene. FOPflash contains mutated
TCF binding sites and is used as a negative control for
TOPflash activity. HUH6 and HUH6shCTNNB1 were culti-
vated in the presence or absence of 2 μg/ml of doxycyc-
line for 72 h and transfected with reporter plasmids
using Lipofectamine2000 in triplicate in accordance with
the manufacturer’s instructions. The pRL-TK plasmid
(Promega, Madison, WI) was co-transfected to control
for transfection efficiency. Forty-eight hours after trans-
fection, Luciferase activity was measured with the Dual-
Luciferase reporter assay system (Promega).
Real Time quantitative PCR
Total RNA was isolated with TriZol reagent according
to the manufacturer’s instructions (Life Technologies).
Reverse transcription was performed from 1 μg of total
RNA with the Transcriptor First Strand cDNA Synthesis
Kit (Roche Diagnostics, Basel, Switzerland) and random
hexamer primers. PCR amplification was performed on
the LightCycler 480 system with SYBRGreen PCR mix
(Roche Diagnostic) and the following primers: HGS for-
ward 5’- CTCCTGTTGGAGACAGATTGGG -3’ and H
GS reverse 5’- GTGTGGGTTCTTGTCGTTGAC -3’, 18S
forward 5’-GTAACCCGTTGAACCCCATT-3’ and 18S
reverse 5’-CCATCCAATCGGTAGTAGCG-3’, CTNNB1
forward 5’- GCTTTCAGTTGAGCTGACCA-3’ and CTN
NB1 reverse 5’-GCTTTCAGTTGAGCTGACCA-3’ or
Axin2 forward 5’- TGTCTTAAAGGTCTTGAGGGTTG
AC-3’ and Axin 2 reverse 5’- CAACAGATCATCCCAT
CCAACA-3’.
Transcriptome analysis
After validating RNA quality with the Bioanalyzer 2100
(using Agilent RNA6000 nano chip kit), 50 ng of total
RNA was reverse transcribed with the Ovation PicoSL
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WTA System V2 (NuGEN, San Carlos, CA). Briefly, the
resulting double-stranded cDNA was used for amplifica-
tion based on SPIA technology. After purification
according to the manufacturer’s protocol, 2.5 μg of
single-stranded DNA was fragmented and labeled with
biotin using the Encore Biotin Module (NuGEN). Frag-
ment size was verified with the Bioanalyzer 2100, cDNA
was then hybridized to GeneChip® human Gene 1.0 ST
(Affymetrix) at 45 °C for 17 h. After overnight
hybridization, the chips were washed on the fluidic sta-
tion FS450 according to the manufacturer’s protocol
(Affymetrix, Santa Clara, CA) and scanned with the
GCS3000 7G. The image was then analyzed with Expres-
sion Console software (Affymetrix) to obtain raw data
(cel files) and metrics for quality control. The evaluation
of some of these metrics and the distribution of raw data
showed no experimental outliers. RMA normalization
was performed with R.
High-content siRNA screening
A kinome siRNA library of 2748 siRNAs targeting 687
genes (four siRNAs per gene) was obtained from Qiagen.
We also included a negative siRNA control (anti- lucifer-
ase, GL2) and a positive lethal siRNA (anti-KIF11) on
each plate. A total of 750 cells were seeded on a 384-
well plate (View Plates, Perkin Elmer) in 40 μL of
DMEM medium supplemented with 10 % fetal bovine
serum and 1 % penicillin/streptomycin. Cells were trans-
fected the day after with 10 nM siRNA using INTER-
FERin, (0.1 μl per well; Polyplus Transfection, Illkirch,
France). Transfection efficiency was estimated by com-
paring 4,6-diamidino-2-phenylindole (DAPI) staining be-
tween cells transfected with negative control siGL2 and
those transfected with siKIF11. Cells were fixed 72 h
after transfection with 4 % (w/v) formaldehyde for
15 min and washed with phosphate buffered saline
(PBS). Cells were next quenched with 0.05 M NH4Cl
and permeabilized first with a PBS solution containing
0.2 % BSA and 0.05 % saponin, and subsequently with
0.5 % Triton-X100. Cells were then incubated for 60 min
with rabbit primary antibody anti-cleaved Caspase 3
(1:500; Sigma-Aldrich) and mouse anti-Ki67 (1:500;
Millipore). Next, cells were washed twice in PBS and in-
cubated with Alexa Fluor 488- or Cy3 coupled secondary
antibodies (Jackson ImmunoResearch). Nuclei were
stained with 0.2 μg/ml DAPI. Images were acquired with
an INCell2000 automated wide-field system (GE Health-
care,) at 10x magnification (Nikon 10X/0.45, Plan Apo,
CFI/60). Images were analyzed with the INCell Analyzer
workstation software (GE Healthcare) and the mean
fluorescence intensity of nuclear Ki67 (a proliferation
marker) and cleaved-caspase3 antigens was quantified in
each cell. Three independent experiments were per-
formed for each treatment.
Data analysis and hit calling
Positive hits for each gene were identified as follows. Data
were first transformed with log or logit functions. B-score
normalization was then applied to each replicate, separ-
ately, and included corrections for plates, rows and col-
umns [10, 11]. Median and median absolute deviation
(MAD) were computed and used to compute Robust Z-
scores (RZ-scores) for each sample, according to the for-
mula: score = (value - median)/(1.4826 * Median MAD)
[12]. RZ-scores were calculated for the comparison of
each siRNA against the GL2 negative control population.
A gene was identified as a ‘hit’, if the RZ-score for at least
two of four siRNAs was > 2 or < -2 in at least two of three
replicates. Selected hits were further reordered and vali-
dated with four siRNAs per gene (Qiagen), for HUH6 and
HUH6shCTNNB1 cell lines treated or not treated with 2 μg/
ml doxycycline.
Crystal violet assay
HuH6shCTNNB1 cells were cultured with 2 μg/ml of doxy-
cycline for 48 h prior to siRNA transfection and were
kept in the presence of doxycycline for the following
72 h. HCTT116, HuH6 and HuH6shCTNNB1 cells were
plated at 0.1 × 106 cells per well on 6-well plates and
transfected with siRNA as indicated. Seventy-two hours
after transfection, cells were washed once in PBS and in-
cubated in a crystal violet solution (0.5 % crystal violet,
20 % methanol) for 10 min at room temperature. Plates
were washed once with PBS and twice by immersion in
water. Cells were then incubated in 1 % SDS solution
until the dye was completely solubilized and absorbance
was read at 570 nm.
Apoptosis assay
Cells were harvested and centrifuged at 200 g for 5 min
and the pellet was resuspended in 500 μl of culture
medium containing 200nM 3,3'-Dihexyloxacarbocyanine
iodide (DiOC6(3)) and 7.5 μM propidium iodide (PI),
(Life Technologies). Cells were incubated for 20 min at
37 °C and samples were analysed using a BD LSR For-
tessa flow cytometer (BD Biosciences, San Jose, CA).
Cell cycle assay
Cells were harvested and fixed with ice cold ethanol
70 % for 20 min, stained with 7.5 μM PI solution con-
taining 100 μg/ml of RNAseI, and then analysis were
performed with a BD LSR Fortessa flow cytometer.
Immunoblot analysis
Cells were washed in ice-cold PBS and lysed in RIPA
buffer (Sigma-Aldrich) containing 1X of complete prote-
ase inhibitor cocktail (Roche Diagnostics) and centri-
fuged at 13,000 g for 10 min at 4 °C. Total proteins were
resolved by SDS-PAGE, transferred to nitrocellulose and
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blocked with 5 % BSA. Blots were separately incubated
overnight at 4 °C with specific primary antibodies, including
1:1000 anti-HGS/HRS (from Bethyl Laboratories, Mont-
gomery, TX), 1:5000 anti-β-catenin (BD Transduction
Laboratories, Franklin Lakes, NJ), 1:5000 anti-γ tubulin and
1:5000 anti-β-Actin (Sigma-Aldrich). After further washing
and incubating with corresponding secondary antibodies,
the blots were developed by enhanced chemiluminescence
(Thermo Fisher Scientific, Waltham, MA).
Results and discussion
Identification of liver cancer cell lines with high β-catenin
signaling activity
Oncogenic mutations of β-catenin are a frequent event
in liver cancer. In this study, we used an siRNA-based
loss-of-function screen to identify kinases and proteins
related to kinases that are specifically required for the
survival of cells in which β-catenin signaling is deregu-
lated. First, we measured β-catenin-induced Tcf/Lef
transcriptional activity in liver cancer cell lines with a
dual-luciferase assay to identify pertinent cell lines for
HT-screening. We selected liver cancer cell lines with
alterations in CTNNB1 (point mutations such as
CTNNB1S37C and CTNNB1G34V found in SNU398 and
HuH6 cells, respectively, or a CTNNB1ΔW25_I140 dele-
tion found in HepG2 cells), and a cell line with a WT
CTNNB1 gene (HCC HuH7 cells). HeLa and Human
Embryonic Kidney 293 T cells (HEK293T) were used as
negative controls. Only background activity was detected
in HeLa and HEK293T cells, whereas HuH7 cells showed
modest but significant β-catenin co-transcriptional activ-
ity, despite the WT status of β-catenin (Fig. 1), which may
be caused by autocrine Wnt signaling in HuH7 cells [13].
Cell lines harboring CTNNB1 mutations showed great dis-
parity in basal β-catenin signaling activity. SNU398 cells
showed rather weak β-catenin transactivation (3.6 times
higher than background levels, similar to HuH7 cells),
whereas activity was 8- and 36-fold higher than back-
ground levels in HepG2 and HuH6 cells, respectively
(Fig. 1). Therefore, HuH6 cells were subsequently selected
for HT-screening as a reference cell line with high β-
catenin signaling activity.
Generation of a stable HuH6 cell line with doxocycline-
inducible sh-RNA against CTNNB1
We sought to identify SL interactions involving onco-
genic β-catenin activity; therefore, we transfected HuH6
cells with pTER-sh-β-catenin encoding a Doxycycline
(Dox)-regulated shRNA against CTNNB1 [9], to obtain
HuH6 cells with low β-catenin activity. HuH6 clones
containing a stably integrated shRNA vector were
selected by culture in the presence of 5 μg/ml puro-
mycin for four weeks. We then analyzed the abundance
of β-catenin expression in selected clones treated with
Dox by western blotting. The HuH6_5G clone showed
the lowest levels of β-catenin (Fig. 2a). The abundance
of CTNNB1 mRNA in the HuH6_5G clone was 40 %
lower in cells treated for 5 days with Dox than in control
cells, confirming the efficiency of the shRNA (Fig. 2b).
Additional experiments showed that β-catenin signaling
was strongly impaired in the Dox-treated HuH6_5G
clone. RT-qPCR experiments showed that AXIN2 (a dir-
ect target of TCF/LEF/β-catenin complex [14, 15])
mRNA levels were 80 % lower in HuH6_5G cells treated
for 5 days with Dox than in untreated (no Dox) control
cells (Fig. 2c). In addition, we compared gene expression
profiles between untreated and Dox-treated HuH6_5G
cells by Affymetrix DNA microarrays: several genes that
are known to be activated by β-catenin were significantly
down-regulated in cells expressing shRNA against
CTNNB1 (Table 1 and Additional file 1: Table S1), indi-
cating that β-catenin signaling activity was impaired in
these cells. Finally, TCF/LEF luciferase reporter activity
was substantially lower in Dox-treated HuH6_5G than
in control cells (Fig. 2d), confirming that β-catenin sig-
naling is weak when shRNA expression is induced in re-
sponse to Dox treatment in HuH6_5G cells.
Surprisingly, the almost complete inhibition of β-
catenin signaling activity did not appear to correlate with
β-catenin protein levels (which were only 40 % lower in
Dox-treated cells than in control cells). This may be
explained by the dual role of β-catenin at the plasma
membrane, where it has a structural function in
cadherin‐based adherens junctions [16]. Indeed, the
remaining β-catenin protein in Dox-treated cells is likely
to be trapped in cadherin-based adherent junctions and
Fig. 1 β-Catenin transactivation level in human HCC and HB cell
lines. Hepatocellular carcinoma cell lines (HepG2 and SNU398),
hepatoblastoma cell lines (HuH6 and HuH7), Human embryonic
kidney 293 T cell line and human cervical carcinoma HeLa cell line
were transfected with either TOPFlash luciferase (black rows) or
FOPFlash luciferase (gray rows) reporter plasmids. Firefly luciferase
activity was assessed 24 h after transfection in whole cell extracts
and normalized to Renillia luciferase activity
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thus not able to activate genes transcription (β-catenin
signaling is close to basal level in Dox-treated cells). Fur-
thermore, we observed that β-catenin signaling was simi-
lar between parental HuH6 and untreated-HuH6_5G cells
(compare Figs. 1 and 2d). For clarity, the HuH6_5G clone
is hereafter named HuH6shCTNNB1. Thus, parental Huh6
and HuH6shCTNNB1 (without Dox) were used as reference
cells with a high β-catenin signaling activity and Dox-
treated HuH6shCTNNB1 cells were used as reference cells
with low β-catenin signaling activity.
The impairment of β-catenin signaling in Dox-treated
HuH6shCTNNB1 cells was associated with a substantial cell
growth defect when cells were seeded at very low density
(Additional file 2: Figure S1-A), whereas cell growth was
not significantly affected when cells were seeded at medium
density (Additional file 2: Figure S1-B). In order to explain
the slow increase of Dox-treated HuH6shCTNNB1 in culture,
we performed cell cycle analysis by measuring DNA con-
tent in HuH6shCTNNB1 treated or not with Dox by flow
cytometry after PI staining (Additional file 2: Figure S1 C-
D). We did not detect any significant difference between
Dox-treated and untreated HuH6shCTNNB1 when seeded at
medium density (Additional file 2: Figure S1-D). However,
at low cell density we observed an increase in G0/G1 cells
in Dox-treated HuH6shCTNNB1 when compared to
untreated cells, with a concomitant decrease in G2/M cells
(Additional file 2: Figure S1-C). These data suggest that
a b
c d
Fig. 2 Down regulation of β-catenin expression and inhibition of β-catenin signaling in HuH6pTER-sh-β-catenin transfectant cells. a HuH6 cells were transfected
with pTER-sh-β-catenin and selected with 2 μg/ml puromycin for 4 weeks. After amplification of isolated colonies, resultant HuH6pTER-sh-
β-catenin transfectants were cultivated in the presence or absence of 2 μg/ml doxycycline for 72 h and the abundance of β-catenin in whole
cell extracts was assessed by immunoblotting. b Clone 5G was cultivated in the presence or absence of 2 μg/ml doxycycline for the indicated
times and β-catenin mRNA levels were analyzed by RT-qPCR. c- Clone 5G was cultivated in the presence or absence of 2 μg/ml of doxycycline
for 72 h and Axin2 mRNA levels were analyzed by RT-qPCR. d Clone 5G was cultivated in the presence or absence of 2 μg/ml doxycycline for
72 h and β-catenin/TCF transcriptional activity was assessed by the luciferase reporter assay
Table 1 Target genes activated by Wnt/β-catenin signaling and
down-regulated in HuH6shCTNNB1 in response to Dox treatment.
Gene expression was analyzed with Affymetrix DNA microarrays
and the expression profile of HuH6shCTNNB1 cells treated with Dox
for 2 days was compared with that of untreated HuH6shCTNNB1 cells.
Note that CTNNB1 showed a -0.9 Δlog2 in response to shRNA in-
duction with Dox
Wnt target genes References ΔLog2
AXIN2 [14, 15] −1.25
BMP4 [24] −1.14
NKD1 [25] −1.13
TNFRSF19 [26] −1.12
NOTUM [27] −1.11
ISM1 [28] −1.11
LGR5 [29] −1.03
DUSP6 [30] −1.02
CCND1 [31] −0.93
FGF9 [32] −0.84
MYC [33] −0.66
MMP2 [34] −0.62
HNF1A [35] −0.58
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G0/G1 phase of cell cycle is longer in Dox-treated
HuH6shCTNNB1 when seeded at low density. Yet, this mod-
est difference in cell cycle cannot fully explain the drastic
decrease in Dox-treated HuH6shCTNNB1 growth rate shown
in Additional file 2: Figure S1-A. Therefore, we evaluated
apoptosis by DiOC6(3) and PI co-staining. DiOC6(3) is a
membrane-permeable lipophilic cationic fluorochrome that
is used as a probe for mitochondrial transmembrane poten-
tial (Δψm). In living cells, DiOC6(3) accumulates in mito-
chondria and low DiOC6(3) staining reflects a collapse of
Δψm. Dissipation of mitochondrial transmembrane poten-
tial is a sensitive marker of early apoptotic events. In
addition, PI stains only cells whose plasma membrane in-
tegrity is compromised. Thus, cells that showed low stain-
ing for both DiOC6(3) (loss of Δψm) and PI (loss of plasma
membrane integrity) were considered as apoptotic cells.
Interestingly, we observed a significant increased in number
of apoptotic cells (8.7 % Vs 17.3 %) only in Dox-treated
HuH6shCTNNB1 when seeded at low density (Additional file
2: Figure S1-E). Thus, prolongated G0/G1 phase and sig-
nificant increase of apoptosis could explain the slow growth
rate of Dox-treated HuH6shCTNNB1 when seeded at low
density. Interestingly, these results are consistent with those
of Chan et al. who showed that the inactivation of mutated
CTNNB1 in the colon cancer HCT116 cell line did not
modify the growth of cells passaged under routine condi-
tions, although it significantly decreased colony-forming
ability when plated at low density [17].
HT siRNA screen of HuH6 cells
Kinases play a crucial role in the regulation of Wnt/β-
catenin pathway (and in some cases can be targeted by
chemicals inhibitors) [18]; therefore, we carried out an
siRNA kinome-wide loss-of-function screen (Qiagen,
687 genes - Additional file 3: Table S2) in the HuH6 par-
ental cell line, to identify kinases required for cell viabil-
ity in cells with high β-catenin (Fig. 3a). Each gene was
targeted by four independent siRNAs, resulting in a li-
brary of 2748 siRNAs. Positive (KIF11 siRNA) and nega-
tive (GL2 siRNA) controls were also added. We
examined the effect of silencing on cell growth by high-
content immunofluorescence imaging with DAPI stain-
ing and specific antibodies against Ki67 (cell prolifera-
tion marker) and cleaved caspase 3 (apoptosis).
Each screen was repeated three times to obtain bio-
logical replicates. Results are expressed as median Z-
scores for each siRNA. All siRNAs with a median Z-score
>2 or < −2 were considered significant hits, and genes with
at least two (out of four) ‘hit’ siRNAs were selected as
candidate genes (Fig. 3a). Overall, 52 kinases important
for cell proliferation and/or cell viability were identified
(Additional file 3: Table S2), which represents 7.7 % of
identified kinases and associated proteins tested during
the screening procedure. These results are consistent with
previous reports involving other cancer cell lines [19]. As
expected, survival kinases such as those involved in cell
cycle progression (e.g. AURKB, CDK3, CDK4, CDK5,
CDK7, PLK3, PKMYT1) or in the control of cell growth
(e.g. ADK, RPS6KA2) were identified as hits in our pri-
mary screen. However, depletion of such cell cycle or cell
growth rate related-kinases is likely to be deleterious in
wild type cells as well.
Identification of SL interactions involving oncogenic β-
catenin signaling in HuH6 cells
We then carried out an SL counter-screen with
siRNA against the 52 survival kinases to identify
kinases whose inhibition would affect the viability of
HuH6 cells with oncogenic β-catenin activity, but not
that of HuH6 cells with low β-catenin activity (sh-in-
duced knock-down of β-catenin). A scheme of the
counter-screen is illustrated in Fig. 3b. Briefly, HuH6
and HuH6shCTNNB1 were cultivated for 5 days in the
presence or absence of Dox, and screened with siRNA
targeting the 52 kinases identified in the primary
screen. Thus, this counter-screen included three ex-
perimental conditions with high β-catenin activity
(HuH6, HuH6 + Dox, and HuH6shCTNNB1 cells) and
one with low β-catenin activity (HuH6shCTNNB1 + Dox
cells). Proliferation index was slightly lower in
HuH6shCTNNB1 + Dox cells than in the other three
conditions and was strongly influenced by cell density
(Additional file 2: Figure S1); therefore, the number
of cells/well during the seeding step was optimized to
obtain the same number of cells for each condition
during the transfection step, with similar growth rate
in each experimental condition (Additional file 4:
Figure S2). Cell transfection, cell staining, immuno-
fluorescence imaging and statistical analysis were car-
ried out with similar methods used in the primary
screen and three independent experiments were per-
formed. Genes were classified as a potential SL part-
ner of the activated form of β-catenin if (i)|median
robust Z-score| > 2 for at least two phenotypes in
each high β-catenin signaling condition (HuH6,
HuH6 + Dox, HuH6shCTNNB1), and for at least two
siRNAs; and (ii) knockdown had no significant effect
(|median robust Z-score| < 2) in cells with low β-ca-
tenin signaling (HuH6shCTNNB1 +Dox) for all phenotypes
analyzed. This counter-screen identified five genes that
are potential SL partners of oncogenic β-catenin (Table 2):
HGS (hepatocyte growth factor-regulated tyrosine kinase
substrate), STRADA (STE20-related kinase adaptor
alpha), FES (feline sarcoma oncogene), BRAF (v-raf
murine sarcoma viral oncogene homolog B) and
PKMYT1 (protein kinase, membrane associated tyro-
sine/threonine 1).
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HGS is required for the survival of liver cancer cell lines
with oncogenic mutations in CTNNB1
We investigated biological effect of the five identified
candidates. First, we performed the knockdown of
HGS, STRADA, FES, BRAF and PKMYT1 by RNAi
experiments in HuH6shCTNNB1 (high β-catenin signal-
ing) or in Dox-treated HuH6shCTNNB1 (low β-catenin
signaling) and assessed cell survival by crystal violet
staining (Additional file 5: Figure S3). We observed
that HGS depletion had the stongest inhibitory effect on
cell growth specifically in cells with high β-catenin activity.
However, the crystal violet assay is not a sensitive method
for the estimation of cell survival. Indeed, we cannot dis-
criminate between adherent living and adherent dead cells
with this assay. By flow cytometric experiments, we mea-
sured a two-fold increase of apoptotic cells following HGS
knockdown in high β-catenin signaling HuH6shCTNNB1 com-
pared to scramble siRNA, while siRNA against HGS did not
modify proportion of apoptotic cells in HuH6shCTNNB1 +
Dox (Fig. 4b and Additional file 6: Figure S4). These data
were confirmed by Western blot analysis of cleaved-
caspase 3 expression, a specific marker of apoptotic cells.
a
b
Fig. 3 siRNA screen based on immunofluorescence imaging. a Identification of kinases required for HuH6 viability. A kinome siRNA library was
used to transfect HuH6 cells: 687 genes were individually targeted (four siRNAs per gene) and three independent experiments were performed.
Cells were immunolabeled 72 h after transfection with anti-cleaved caspase 3 (apoptosis marker) and anti-Ki67 (cell proliferation markers) antibodies
and nuclei were labeled with DAPI (cell count) before the acquisition of images and readout of phenotypes. Three phenotypes were analyzed: (i)
cell numbers through DAPI staining, (ii) Apoptosis and (iii) G0-phase arrest with Ki67. All siRNAs with median Z-scores >2 or < −2 were
considered significant hits, and genes with at least two (out of four) ‘hit’ siRNAs were selected as candidate genes. Following this screen,
52 genes were identified as necessary for HuH6 survival or proliferation. The 52 outliers are listed in Table S2, additional Excel file b Counter-screen:
Investigation of synthetic lethality relationship between candidate genes and stabilized β-catenin. HuH6 and HuH6shCTNNB1 were cultured in the
presence or absence of 2 μg/ml doxycycline 72 h, and transfected with a siRNA library including the 52 outliers identified in the primary screen (four
siRNAs per gene). Each screen was repeated three times to obtain biological replicates. Transfection was carried out and phenotypes were assessed as
described in A. Outliers were called if |robust Z-score| > 2 for at least two phenotypes and two out of four siRNAs, only in cells with high β-catenin
signaling. Following the counter-screen, five genes (listed in Table 2) were identified as having a potential lethal synthetic relationship with
mutant β-catenin
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Indeed, cleaved-caspase 3 was only detected after HGS
knockdown performed in high β-catenin signaling cells
(Fig. 4c). Finally, to show that deleterious effect of HGS
depletion truly depends on oncogenic β-catenin mutant,
we performed HGS knockdown in HuH7 which is a hepa-
toblastoma cell line with wild-type β-catenin. HGS protein
expression was efficiently impaired by HGS_1 siRNA in
HuH7 (Fig. 4e). However, HGS depletion did not induce
apoptosis as indicated by the proportion of DiOC6(3)/PI
double negative cells measured by flow cytometry (Fig. 4d)
and by the absence of cleaved-caspase 3 expression
(Fig. 4e). Altogether, our data showed that HGS is SL part-
ner of oncogenic β-catenin and its depletion induces apo-
tosis in hepatoblastoma cell lines.
HGS is required for the survival of CRC cell lines with
oncogenic mutations in CTNNB1
We decided to analyze SL interactions with oncogenic
CTNNB1 in a different cellular context, the human
colorectal cancer cell line HCT116, to determine the
specificity of the five potential SL partners of activated-β-
catenin. Parental HCT116 is heterozygous for CTNNB1
(CTNNB1WT/del45) and has one WT allele and one mutant
allele with a 3-bp deletion that eliminates the serine resi-
due at codon 45, leading to synthesis of mutant β-catenin
which is constitutively active [17]. In parallel, we used
genetically modified HCT116_CTNNB1WT/- cells with
low β-catenin activity in which the CTNNB1del45 allele is
invalidated [17]. We first performed siRNA experiments
for the five targets identified during the SL screen to verify
the efficiency of silencing in HCT116 cells by RT-qPCR
(Additional file 7: Figures S5). We then estimated cell sur-
vival by the crystal violet assay 72 h after transfection of
HCT116WT/del45 and HCT116WT/- cells with the most ef-
ficient siRNA against one of the five potential SL partners
of oncogenic β-catenin. Depletion of STRADA, FES, BRAF
and PKMYT1 affected cell survival in both HCT116WT/
del45 and HCT116WT/-, whereas HGS knockdown signifi-
cantly impaired cell survival only in HCT116WT/del45 (high
β-catenin signaling cells) (Additional file 8: Figure S6).
Indeed, HGS knockdown efficiently impaired the accumu-
lation of HGS mRNA and protein in both cell lines
(Fig. 5a-b); however, the density of HCT116WT/del45 cells
depleted of HGS was 42 % lower than that of control cells,
whereas HCT116WT/- cell density was unaffected by HGS
depletion (Fig. 5c). Moreover, HGS knockdown in
HCT116WT/del45 leads to a significant increase in apop-
totic cells number (11.6 % Vs 16.6 %), suggesting that
HGS expression is required for HCT116WT/del45 survival
(Fig. 5d). Intriguingly, the abundance of HGS mRNA was
higher in HCT116WT/del45 cells than in HCT116WT/- cells
(Fig. 5a), which suggest that HGS expression is in part
positively regulated by β-catenin in HCT116 cells (directly
or indirectly). However, HGS protein levels were not sig-
nificantly different between HCT116WT/del45 and
HCT116WT/- cells (Fig. 5b). Thus, the potential regulation
of HGS by β-catenin cannot fully explain the SL relation-
ship between these two genes. Our results obtained in the
colorectal HCT116 cell line support the existence of an
SL relationship between HGS and oncogenic mutations in
β-catenin and identify HGS as a potential therapeutic tar-
get for cancers with mutations in CTNNB1, which is a fre-
quent event in liver cancer.
HGS (also called HRS for Hepatocyte growth factor-
regulated tyrosine kinase substrate) is an essential protein
that belongs to multi-vesicular bodies (MVB)/Lysosome
complex, which is required to sort membrane proteins
and direct them toward either degradation in lysosomes
or recycling at the plasma membrane [20, 21]. Interest-
ingly, Toyoshima et al. showed that depletion of HGS in
fibroblasts led to a defect in E-cadherin degradation and
accumulation of E-cadherin at the plasma membrane,
which in turn trapped β-catenin at the membrane, pre-
venting its translocation to the nucleus. In addition, HGS
depletion attenuates the cell growth, tumorigenesis and
metastatic potential of Hela cells [22]. Therefore, it is
plausible that HGS depletion in HuH6 cells leads to the
accumulation of E-cadherin at the plasma membrane,
Table 2 List of the five genes identified by HT screening as important for the cellular fitness of high β-catenin signaling cells (HuH6) but
not for low β-catenin signaling (HuH6shCTNNB1 +Dox) cells. All siRNAs with a median RZ-scores < −2 or >2 were considered hits. Genes were
considered as hits if at least two of the four siRNAs were siRNA hits, for at least two phenotypes (cell proliferation, apoptosis or mitotic
events) in high β-catenin signaling cells (HuH6, HuH6 + Dox, HuH6shCTNNB1), but not in low β-catenin signaling cells (HuH6shCTNNB1 +Dox).
The RZ-score for the best siRNA hits/gene is shown
Cell count Apoptosis Mitotic events
Genes
Hits
HuH6 HuH6+
Dox
HuH6shCTNNB1 HuH6shCTNNB
+ Dox
HuH6 HuH6+
Dox
HuH6shCTNNB1 HuH6shCTNNB
+ dox
HuH6 HuH6+
Dox
HuH6shCTNNB1 HuH6shCTNNB
+ Dox
HGS −3.62 −3.11 −3.49 2.33 2.69 2.02 −2.11
STRADA −2.64 −4.08 −5.1 3.15 3.11 3.62 3.31
FES −2.63 −2.71 −2.44 2.22 2.24 2.11 −2.33
BRAF −2.57 −2.83 −2.86 2.77 2.63 2.29
PKMYT1 −2.51 −2.21 −2.31 3.43 3.98 3.87
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c
d e
Fig. 4 HGS knockdown impairs cell viability specifically in hepatoblastoma cells with high β-catenin signaling. a HuH6shCTNNB1 cells were cultured
in the presence or absence of 2 μg/ml doxycycline for 96 h, seeded in 12-well plate and transfected with scramble or siRNA targeting specifically
HGS and cultured for 72 h. Untransfected cells (siRNAimax lipofectamine alone) were also included as a control. Cell density was estimated 72 h
after cell transfection by crystal violet staining. b Cells were cultured and transfected as in A and were stained with DiOC6(3) and PI. Proportion of
apoptotic cells was determined by flow cytometric experiment. Note that apoptotic cells showed low labelling for both DiOC6(3) and PI. Means of
three independent experiments are shown. c Cells were treated as in A and cleaved caspase3, HGS and β − actin protein levels were examined by
immunoblotting. d HuH7 were transfected with scramble or siRNA targeting specifically HGS and cultured for 72 h. Untransfected cells (siRNAimax
lipofectamine alone) were also included as a control. Proportion of apoptotic cells was determined by flow cytometric experiment after DiOC6(3)/IP
staining. e HuH7 cells were transfected as in D and cleaved caspase3, HGS and β − actin protein levels were examined by immunoblotting. Protein
extract from HuH7 treated with 2 μg/ml doxorubicin for 16 h was added as positive control for cleaved caspase3 expression
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which may trap the stabilized form of β-catenin,
thus impairing signaling through this pathway and
attenuating its oncogenic effect. However, HGS is
also a key regulator of the molecular machinery in-
volved in receptor sorting and recycling; therefore,
HGS depletion may affect several signaling pathways.
Hence, the exact nature of the SL relationship be-
tween oncogenic CTNNB1 and HGS requires further
investigation.
Conclusions
In conclusion, we performed a siRNA screen that led to
the identification of HGS as a potential SL partner of
oncogenic CTNNB1. To ensure high confidence in the
hits selected with our approach, we measured three
fitness variables (cell proliferation index, induction of
apoptosis and number of mitotic events) [23] in two dif-
ferent isogenic cell line pairs from different cellular con-
texts (liver cancer and CRC). Thus, our findings strongly
a
b
c
d
Fig. 5 HGS knockdown impairs cell viability specifically in HCT116 cells with oncogenic mutations in β-catenin. HCT116wt/del (CTNNB1S45del heterozygous)
and HCT116WT/- (CTNNB1WT only) cells were transfected with scramble or siRNA targeting specifically HGS and cultivated for 48 h. Untransfected cells were
also included as a control. a HGS mRNA levels were assessed by RT-qPCR and normalized to the abundance of 18S RNA. The mean ± SD of triplicate
samples is presented. b The abundance of HGS and γ-tubulin protein was examined by immunobloting. c Cell proliferation was visualized by crystal
violet staining 72 h after HGS knockdown. Dye was solubilized in 1 % SDS solution and absorbance was read at 570 nm and quantified. The mean ±
SD of triplicate samples is presented. d Assessment of apoptosis with DiOC6(3) and IP staining. The mean ± SD of three independent experiments
is presented
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suggest the existence of a SL interaction between HGS
and oncogenic CTNNB1 in HuH6 and HCT116 cells;
nonetheless, further investigation is required to validate
HGS as a new therapeutic target for liver cancers with
CTNNB1 mutations.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
Additional files
Additional file 1: Table S1. Affymetrix DNA microarray analysis of gene
expression in HuH6shCTNNB1 cells in response to Dox treatment. Gene
expression profile was analyzed with Affymetrix DNA microarrays and the
expression profile of HuH6shCTNNB1 treated with Dox for 2 days was
compared with that of untreated HuH6shCTNNB1 cells. (XLSX 1641 kb)
Additional file 2: Figure S1. HuH6shCTNNB1 growth rate in response to
Dox treatment is dependent of cell density. A-HuH6shCTNNB1 cells were
cultivated in the presence or absence of 2 μg/ml Dox for 3 days. Cells
were then seeded at 3 × 103 cells per well in 12–well plates and cultivated
in the presence or absence of 2 μg/ml Dox for 7 days. Cell density was
estimated at the indicated times by crystal violet assay and quantified as
indicated in Materials and Methods. A representative picture of four
independent experiments is shown. Results are expressed as the
mean ± S.D. Plain and dashed lines show the growth of HuH6shCTNNB1
cells without and with Dox, respectively. B-HuH6shCTNNB1 cells were
cultivated in the presence or absence of 2 μg/ml Dox for 3 days.
Cells were then seeded at 30 × 103 cells per well in a 12–well plate
and cultivated in the presence or absence of Dox for 7 days. Cell
density was estimated at the indicated times by crystal violet assay.
A representative picture of four independent experiments is shown.
Results are expressed as the mean ± S.D. Plain and dashed lines show
the growth of HuH6shCTNNB1 cells without or with Dox, respectively.
C- HuH6shCTNNB1 cells were cultured in the presence or absence of 2 μg/ml
Dox for 3 days and cells were seeded at low density (0.02 × 106 cells/well in
6-well plates) and cultured for another 24 h. Proportion of cells in G0/G1, S
or G2/M phases was determined by assessment of DNA content with PI
staining and flow cytometry. Black and grey rows represent untreated
HuH6shCTNNB1 and Dox-treated HuH6shCTNNB1 cells, respectively D-
HuH6shCTNNB1 cells were cultured in the presence or absence of 2 μg/ml
Dox for 3 days and cells were seeded at medium density (0. 2 × 106 cells/
well in 6-well plates) and cultured for another 24 h. Proportion of cells in
G0/G1, S or G2/M phases was determined by assessment of DNA content
with PI staining and flow cytometry. Black and grey rows represent un-
treated HuH6shCTNNB1 and Dox-treated HuH6shCTNNB1 cells, respectively E- As-
sessment of apoptosis by flow cytometry with DiOC6(3) and IP staining. Plain
black (untreated) and plain grey (2 μg/ml Dox) columns show apoptosis in
HuH6shCTNNB1 seeded at medium density (0.2 × 106 cells/well), whereas
dashed black (untreated) and dashed grey (2 μg/ml Dox) columns show
apoptosis in HuH6shCTNNB1 seeded at low density (0.02 × 106 cells/well).
Means ± S.D. of three independent experiments are presented. (PDF 172 kb)
Additional file 3: Table S2. List of the 52 genes identified among the
687 tested genes in HT screening as important for the cellular fitness of
parental HuH6 cells. (XLSX 18 kb)
Additional file 4: Figure S2. HuH6 ± Dox and HuH6shCTNNB1 ± Dox
growth rates in 384-well plate. Parental HuH6 and HuH6shCTNNB1 were
cultured in the presence or absence of 2 μg/ml of doxycyclin for 96 h.
Parental HuH6 ± Dox and untreated HuH6shCTNNB1 were seeded at 750
cells/well while HuH6shCTNNB1 + Dox were seeded at 1500 cells/well in
384-well plates. Cell growth rates were assessed at the indicated times
after DAPI staining by counting the nuclei in four different fields per well,
in 24 wells per condition, acquiered at 10x magnification. Note that
HuH6 (plain black line), HuH6 + Dox (dashed black line), HuH6shCTNNB1
(plain grey line) and HuH6shCTNNB1 + Dox (dashed grey line) showed
similar growth rates for at least 72 h. (PDF 89 kb)
Additional file 5: Figure S3. HuH6shCTNNB1 cell growth in response to
knockdown of potential lethal synthetic hits HGS; STRADA, FES, BRAF and
PKMYT1. HuH6shCTNNB1 and Dox-treated HuH6shCTNNB1 cells were trans-
fected with scramble siRNA or with siRNAs specifically designed to target
HGS, STRADA, BRAF, PKMYT1or FES. Untransfected cells were also included
as a control. Cell density was estimated 72 h after cell transfection by
crystal violet staining, and the effect of siRNA on cell proliferation was
determined by the ratio ‘O.D. target siRNA’/ ‘O.D. scramble siRNA’. Gray
and black rows show the proliferation rate of Dox-treated HuH6shCTNNB1
and HuH6shCTNNB1 cells (relative to scamble), respectively. (PDF 91 kb)
Additional file 6: Figure S4. Flow cytometric analysis of apoptotis.
Representative DiOC6(3)/PI dot plots with typical distribution patterns and
gating. Cells gated in P1 were considered as apoptotic cells. Cells with
high PI labelling were considered as necrotic cells (loss of plasma
membrane integrity). Cells with low PI labelling and high DiOC6(3)
labelling were considered as living cells. (PDF 252 kb)
Additional file 7: Figure S5. Validation of siRNA efficiency in HCT116
cells. HCT116WT/S45del cells were transfected with scramble siRNAs or with
four different siRNAs designed to target HGS, STRADA, FES, BRAF or
PKMYT1. Untransfected cells were also included as a control. Forty-eight
hours after transfection, the mRNA levels of these genes were assessed
by RTqPCR and normalized to the abundance of 18S RNA. (PDF 196 kb)
Additional file 8: Figure S6. HCT116WT/S45del and HCT116WT/- cell
growth in response to knockdown of potential lethal synthetic hits HGS;
STRADA, FES, BRAF and PKMYT1. HCT116WT/S45del and HCT116WT/- cells
were transfected with scramble siRNA or with siRNAs specifically
designed to target HGS, STRADA, FES, BRAF or PKMYT1. Untransfected cells
were also included as a control. Cell density was estimated 72 h after cell
transfection by crystal violet staining, and the effect of siRNA on cell
proliferation was determined by the ratio ‘O.D. target siRNA’/ ‘O.D.
scramble siRNA’. Gray and black rows show the proliferation rate of
HCT116WT/S45del and HCT116WT/- cells (relative to scamble), respectively.
Note that cell proliferation was affected by the silencing of each genes,
both in HCT116WT/S45del and HCT116WT/- cells, except for HGS, the
depletion of which affected specifically HCT116WT/S45del cells. (PDF 92 kb)
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